Daily Bulletin

Men's Weekly

.

  • Written by PR Newswire Asia - Daily Bulletin Au RSS

New COVID-19 Medriva Rapid Antigen Test kits with very high- sensitivity now available in Australia

MELBOURNE, Australia, April 8, 2022 /PRNewswire/ -- Medriva; https://medriva.com, a leading global manufacturer of COVID-19 testing and vaccination products, announced the Australian availability of its "very-high-sensitivity" Medriva Rapid Antigen Test Kits, following recent approval by the Australian Therapeutic Goods Administration (TGA). With a sensitivity of 95%, specificity of 99.9%, and the ability to detect all known Omicron variants, the Medriva kits are among the best on the market and are offered at a fraction of the cost of competing products.

Medriva Covid-19 Rapid Antigen Test Kit Medriva Covid-19 Rapid Antigen Test Kit

Australian government agencies, healthcare providers, businesses and consumers can order Medriva Rapid Antigen Test Kits via Medriva's website. They will soon be available via Amazon.com.au and at leading Australian pharmacies and retailers.

Gurbaksh Chahal, chief executive and founder of Medriva's parent company, ProcureNet, said: "Widespread access to fast and affordable COVID-19 testing is crucial as Australia moves into flu season, and as cases of the new BA 2.2 sub-variant appear to be growing in NSW and Queensland. We are pleased to be able to support Australians' return to normal life after a challenging couple of years of lockdowns and restrictions."

Medriva was established in 2020 by global commodities manufacturing platform, ProcureNet, in response to the urgent worldwide need for COVID-19 testing and vaccination equipment. Medriva rapidly scaled production to supply the World Health Organisation, Pan American Health Organisation, UNICEF, Health Canada, Ministero della Difesa, Sinovac and many other global public, private and not-for-profit institutions. Since its launch, Medriva has aided over 1 billion vaccinations. Production is expected to double to 2 billion in 2022, accounting for 20% of all COVID-19 vaccinations administered worldwide.

About Medriva

Founded by serial entrepreneur Gurbaksh Chahal, Medriva; https://medriva.com manufactures and distributes in vitro diagnostics and injection and infusion products, utilising parent company ProcureNet's technology to rapidly scale its global manufacturing capabilities. Medriva's Injections & Infusions division is on track to produce over two billion auto-disabled syringes for multinational clients including PAHO, UNICEF, WHO, and health ministries of more than twenty countries across Asia, Europe & Oceania.

Medriva also manufactures rapid antigen test kits that detect SARS-COV-2 pathogens. The test kits detect both Omicron and Delta variants and have one of the highest sensitivity and specificity in the marketplace. Medriva's rapid test kits are available in thirty countries, with sales exceeding 300 million units.

Authors: PR Newswire Asia - Daily Bulletin Au RSS

Read more https://www.prnasia.com/story/archive/3717376_AE17376_0

Business News

Wang Chuanfu Attends BYD Harmony’s 100th Overseas Store Opening

Dignitaries inaugurate the new store On July 12, 2025, Melbourne, the vibrant pearl of the southern hemisphere, Chairman and President of BYD Co., Ltd. Mr. Wang Chuanfu inaugurated and awarded the ...

Daily Bulletin - avatar Daily Bulletin

Strategic Global Expansion Moves to Overcome the Growth Challenges

Photo by Gabrielle Henderson on Unsplash Australia's startup ecosystem is having a moment in the sun. Out of 1,257 unicorns globally, eight hail from Australia. Yet, trade and economic policy uncerta...

Daily Bulletin - avatar Daily Bulletin

What Is a Restaurant Point of Sale System and Why Every Eatery Needs One

The commercial dining industry is incredibly fast-paced and constantly needs upgrades to attract the target audience. Every entrepreneur in this sector, without exception, faces numerous challenges...

Daily Bulletin - avatar Daily Bulletin

LayBy Deals